These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 33921762)

  • 41. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
    Solomon BJ; Besse B; Bauer TM; Felip E; Soo RA; Camidge DR; Chiari R; Bearz A; Lin CC; Gadgeel SM; Riely GJ; Tan EH; Seto T; James LP; Clancy JS; Abbattista A; Martini JF; Chen J; Peltz G; Thurm H; Ou SI; Shaw AT
    Lancet Oncol; 2018 Dec; 19(12):1654-1667. PubMed ID: 30413378
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Systematic Review and Network Meta-Analysis of Immune Checkpoint Inhibitors in Combination with Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Carcinoma.
    Chen HL; Tu YK; Chang HM; Lee TH; Wu KL; Tsai YC; Lee MH; Yang CJ; Hung JY; Chong IW
    Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33287455
    [TBL] [Abstract][Full Text] [Related]  

  • 43. How to select the best upfront therapy for metastatic disease? Focus on
    Xia B; Nagasaka M; Zhu VW; Ou SI; Soo RA
    Transl Lung Cancer Res; 2020 Dec; 9(6):2521-2534. PubMed ID: 33489815
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Anaplastic Lymphoma Kinase Inhibitors for Therapy of Neuroblastoma in Adults.
    Stiefel J; Kushner BH; Roberts SS; Iglesias-Cardenas F; Kramer K; Modak S
    JCO Precis Oncol; 2023 Aug; 7():e2300138. PubMed ID: 37561984
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Brigatinib and lorlatinib: their effect on ALK inhibitors in NSCLC focusing on resistant mutations and central nervous system metastases.
    Naito T; Shiraishi H; Fujiwara Y
    Jpn J Clin Oncol; 2021 Jan; 51(1):37-44. PubMed ID: 33147606
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Optimal Care for Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: A Review on the Role and Utility of ALK Inhibitors.
    Singh A; Chen H
    Cancer Manag Res; 2020; 12():6615-6628. PubMed ID: 32821158
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System.
    Sisi M; Fusaroli M; De Giglio A; Facchinetti F; Ardizzoni A; Raschi E; Gelsomino F
    Target Oncol; 2022 Jan; 17(1):43-51. PubMed ID: 35025076
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ceritinib Alone for Crizotinib-naive Versus Crizotinib-pretreated for Management of Anaplastic Lymphoma Kinase-rearrangement Non-Small-cell Lung Cancer: A Systematic Review.
    Zhao X; Feng Z; Wang G; Pang H; Wang M
    Clin Lung Cancer; 2018 Nov; 19(6):e945-e956. PubMed ID: 30228011
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study.
    Novello S; Mazières J; Oh IJ; de Castro J; Migliorino MR; Helland Å; Dziadziuszko R; Griesinger F; Kotb A; Zeaiter A; Cardona A; Balas B; Johannsdottir HK; Das-Gupta A; Wolf J
    Ann Oncol; 2018 Jun; 29(6):1409-1416. PubMed ID: 29668860
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ensartinib in advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, two-staged, phase 1 trial.
    Ma Y; Pan H; Liu Y; Zhang Y; Hong S; Huang J; Weng S; Yang Y; Fang W; Huang Y; Xiao S; Wang T; Ding L; Cui L; Zhang L; Zhao H
    J Thorac Dis; 2022 Dec; 14(12):4751-4762. PubMed ID: 36647478
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.
    Hida T; Nokihara H; Kondo M; Kim YH; Azuma K; Seto T; Takiguchi Y; Nishio M; Yoshioka H; Imamura F; Hotta K; Watanabe S; Goto K; Satouchi M; Kozuki T; Shukuya T; Nakagawa K; Mitsudomi T; Yamamoto N; Asakawa T; Asabe R; Tanaka T; Tamura T
    Lancet; 2017 Jul; 390(10089):29-39. PubMed ID: 28501140
    [TBL] [Abstract][Full Text] [Related]  

  • 52. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
    Katayama R; Sakashita T; Yanagitani N; Ninomiya H; Horiike A; Friboulet L; Gainor JF; Motoi N; Dobashi A; Sakata S; Tambo Y; Kitazono S; Sato S; Koike S; John Iafrate A; Mino-Kenudson M; Ishikawa Y; Shaw AT; Engelman JA; Takeuchi K; Nishio M; Fujita N
    EBioMedicine; 2016 Jan; 3():54-66. PubMed ID: 26870817
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Brigatinib in Japanese Patients With ALK-Positive NSCLC Previously Treated With Alectinib and Other Tyrosine Kinase Inhibitors: Outcomes of the Phase 2 J-ALTA Trial.
    Nishio M; Yoshida T; Kumagai T; Hida T; Toyozawa R; Shimokawaji T; Goto K; Nakagawa K; Ohe Y; Seto T; Kudou K; Asato T; Zhang P; Yamamoto N
    J Thorac Oncol; 2021 Mar; 16(3):452-463. PubMed ID: 33248320
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lorlatinib for the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer.
    Yang J; Gong W
    Expert Rev Clin Pharmacol; 2019 Mar; 12(3):173-178. PubMed ID: 30657349
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Profile of alectinib for the treatment of ALK-positive non-small cell lung cancer (NSCLC): patient selection and perspectives.
    Karachaliou N; Fernandez Bruno M; Bracht JWP; Rosell R
    Onco Targets Ther; 2019; 12():4567-4575. PubMed ID: 31354290
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cost-Effectiveness Analysis of 6 Tyrosine Kinase Inhibitors as First-Line Treatment for ALK-Positive NSCLC in China.
    Zhang M; Zheng B; Yang W; Jiang H; Sun X; Zhao Z; Li G; Dong H
    Clin Med Insights Oncol; 2024; 18():11795549241257234. PubMed ID: 38827520
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Successful Treatment with Lorlatinib after the Development of Alectinib-Induced Liver Damage in ALK-Positive Non-Small-Cell Lung Cancer: A Case Report.
    Makimoto G; Kawakado K; Nakanishi M; Tamura T; Kuyama S
    Case Rep Oncol; 2021; 14(1):197-201. PubMed ID: 33776703
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib.
    Watanabe S; Hayashi H; Okamoto K; Fujiwara K; Hasegawa Y; Kaneda H; Tanaka K; Takeda M; Nakagawa K
    Clin Lung Cancer; 2016 Nov; 17(6):528-534. PubMed ID: 27318655
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Anaplastic lymphoma kinase inhibition in metastatic non-small cell lung cancer: clinical impact of alectinib.
    Muller IB; de Langen AJ; Giovannetti E; Peters GJ
    Onco Targets Ther; 2017; 10():4535-4541. PubMed ID: 28979145
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeting ALK Rearrangements in NSCLC: Current State of the Art.
    Peng L; Zhu L; Sun Y; Stebbing J; Selvaggi G; Zhang Y; Yu Z
    Front Oncol; 2022; 12():863461. PubMed ID: 35463328
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.